The clinical stage drug developer reported progress in its addiction treatment program, with regulatory submission on track for late 2026. Despite improved cash position, losses continued as R&D investments persisted.
The healthcare company is supporting Addiction Awareness Week, highlighting the unmet medical need in addiction disorders and its focus on developing a treatment for binge eating disorder and substance use disorders.
The clinical stage therapeutics company will release its half-year results on 3 December 2025.
The clinical-stage therapeutics company reports progress in scaling up manufacturing for its Ox-1 addiction treatment programme.
The healthcare company has announced a change in its major shareholding structure.
The non-executive director of the biotechnology company has increased his stake through a personal investment vehicle.
The clinical-stage drug development company shares its plans to participate in industry and investor conferences during Q4 2025.
The healthcare company reports a change in shareholding, with Spreadex Ltd increasing its stake in the firm.
The healthcare company reports a change in shareholding, with Spreadex LTD increasing its stake to 4.33% of the voting rights.
The clinical-stage therapeutics company Theracryf Plc has received a patent grant for its Ox-1 program in Korea and reports positive development progress, including an optimal formulation and selection of a second preclinical species.